This week, several stocks caught investors’ attention, driven by significant developments and market momentum. Here’s the breakdown of this week’s trending stocks:
10x Genomics ($TXG) Partners with Anthropic
10x Genomics ($TXG) announced a collaboration with Anthropic, the creator of Claude, to integrate its single cell and spatial biology tools into Claude for Life Sciences. The partnership allows researchers to analyze complex biological data through natural language instead of code, making 10x’s advanced tools more accessible to scientists without computational backgrounds.
According to the companies, the integration connects 10x’s cloud analysis platform directly with Claude, enabling researchers to perform tasks like alignment, clustering, and feature generation conversationally. 10x said the move aims to “remove technical barriers” and help scientists focus on discovery rather than data processing.
Anthropic added that combining AI and human expertise will accelerate progress across fields from hypothesis generation to disease research.
Stock Price Reaction
$TXG shares rose 11% following the announcement
Google ($GOOG) Unveils Quantum Breakthrough
Google ($GOOG) announced that its Willow quantum chip has achieved the first-ever verifiable quantum advantage, running an algorithm called Quantum Echoes that can outperform the fastest classical supercomputers. According to the company, the algorithm computed molecular structures 13,000 times faster than traditional methods, marking a key step toward real-world quantum applications.
The Quantum Echoes algorithm measures how disturbances spread through a quantum system, a process Google says could help model molecular interactions relevant to drug discovery, materials science, and energy research. The results, published in Nature, were verified through experiments in partnership with the University of California, Berkeley.
Google described the achievement as “a foundation for scalable verification” — meaning other quantum systems can reproduce the results, a milestone that moves the field beyond theoretical claims of advantage.
Stock Price Reaction
Despite the scientific milestone, $GOOG shares were little changed, showing no major price movement following the announcement.
Celcuity ($CELC) Surges After Strong Phase 3 Breast Cancer Results
Celcuity ($CELC) announced strong Phase 3 data for its drug gedatolisib, showing significant benefits for patients with advanced hormone receptor–positive, HER2-negative breast cancer.
According to the company, patients treated with gedatolisib combinations lived five to seven months longer without disease progression compared to the current standard treatment. These improvements were seen across multiple patient groups and came with low rates of serious side effects.
Celcuity said the results suggest gedatolisib could become a new standard of care for patients whose disease has progressed after prior treatments. The company has already begun the process of submitting its New Drug Application (NDA) to the FDA, with full results expected in 2026.
Stock Price Reaction
$CELC stock closed up 35% following the announcement.
This article is for informational purposes only and is not investment advice or a solicitation to buy or sell securities. The content is based on publicly available information and reflects the author’s opinions as of the publication date, which may change without notice. All investments carry inherent risks, including the potential loss of principal, and past performance is not indicative of future results. Forward-looking statements, including references to projected revenues, market trends, or business developments, are based on current expectations and assumptions. Actual results may differ due to various factors, including regulatory changes, economic conditions, competitive pressures, and unforeseen market fluctuations. Readers should conduct their own research or consult a financial advisor before making investment decisions. BBAE holds no position in the securities mentioned, nor are they compensated by the companies mentioned.
